Catch up on the top radiology content of the past week.
|Articles|July 19, 1995
FDA committee recommends Merck's Fosamax
A Food and Drug Administration advisory committee last week recommendedapproval of Merck's Fosamax drug for the treatment of osteoporosis.If Fosamax is approved by the FDA, it is expected to give a boostto vendors of dual-energy x-ray absorptiometry
Advertisement
A Food and Drug Administration advisory committee last week recommendedapproval of Merck's Fosamax drug for the treatment of osteoporosis.If Fosamax is approved by the FDA, it is expected to give a boostto vendors of dual-energy x-ray absorptiometry (DEXA) scanners,such as Lunar and Hologic. Merck last month announced financingagreements with the companies to help promote sales of bone densitometrydevices (SCAN 7/6/95).
Advertisement
Related to this article
In addition to providing higher SNRs in vascular structures and parenchymal organs than energy-integrating detector CT, photon-counting CT enabled an approximately 30 percent reduction in volume CT dose index (CTDIvol) for patients with obesity, according to a new study.
Facilitating enhanced 3D visualization of skeletal anatomy, the BoneEnhance machine learning module reportedly provides automated segmentation of bone and surrounding tissues for the Accuro XV ultrasound system.
Newly published preclinical research signals a substantial conceptual shift with a potential role of photon-counting CT in targeting specific biological processes.
The future of AI in radiology lies in its potential capability to forge connections and enhance efficiencies for enterprise-wide workflows.
In a new podcast episode, Joseph Cavallo, MD, MBA, offered his perspective on AI integration, potential efficiency gains, navigating post-deployment monitoring and how to incorporate AI literacy into radiology resident training.
The FFR-IQ software recently demonstrated a 92.2 percent sensitivity for non-invasive estimation of fractional flow reserve (FFRC) based on coronary CT angiography (CCTA) scans.
A Kaiser score > 5 with breast MRI demonstrated a 97 percent sensitivity and 87.9 percent specificity for predicting malignancy in patients with BI-RADS 0 or 4 presentations on mammography and breast ultrasound, according to a new study.
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
FDA Clears Machine Learning Module for Emerging Musculoskeletal Ultrasound Platform
2
Can MRI-Based AI Have an Impact in Reducing Unnecessary Prostate Biopsies?
3
FDA Clears MRI-Based AI Software for Prognostic Evaluation of Patients with Mild Cognitive Impairment
4
Diagnostic Imaging's Weekly Scan: October 18 — October 24
5